Avalon Quantum AI

Avalon Quantum AI is a biotechnology company focused on integrating generative artificial intelligence and quantum computing to accelerate drug discovery and protein design. As a subsidiary of Avalon GloboCare, the company utilizes its proprietary AI platform to predict protein-protein interactions and design novel therapeutic candidates, particularly in the fields of oncology and cellular therapy. By combining quantum-inspired algorithms with biological data, Avalon Quantum AI aims to significantly reduce the time and cost associated with traditional drug development cycles. The company's technology is applied to the development of Flash-CAR T-cell therapies and other advanced biologics. Its lead initiatives involve the in silico design of high-affinity binders for targets such as CD19 and CD22. Through these innovations, Avalon Quantum AI seeks to establish a more efficient pathway for bringing precision medicines to the clinic.